EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Population pharmacokinetics of intravenous fosfomycin: dose optimization for critically ill patients with and without kidney replacement therapy

Katharina M Götz iD, Sascha Kreuer, Anke-Katrin Volz, Suzanne L Parker, Jason A Roberts, George Dimopoulos, Thomas Dimski, Detlef Kindgen-Milles, Lisa K V Beuche, Jan T Kielstein, Thorsten Lehr iD

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.01779-24 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Katharina M Götz und 10 weiteren Autor:innen. Beteiligte Einrichtung: Saarmetrics GmbH, Saarland University, Saarbrücken, Germany. Hauptthemen laut MEDLINE: Fosfomycin, Anti-Bacterial Agents, Renal Replacement Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We investigated the pharmacokinetics (PK) of intravenous fosfomycin in critically ill patients undergoing different types of kidney replacement therapy (KRT) to identify optimized dosing regimens for patient care. Four prospective, observational studies contributed data of critically ill patients with prolonged-intermittent KRT (PIKRT, n =18), continuous KRT (CKRT, n =15), or without KRT ( n =12) for population PK analysis. Subsequently, licensed daily dosages (12–24 g), varying estimated glomerular filtration rates (eGFR, 0–120 mL/min/1.73 m 2 ), and scenarios with or without KRT were simulated for comparison against minimum inhibitory concentrations (MICs, 32–256 mg/L). A dosing regimen was considered “effective” if the ratio of area under the concentration–time curve from 24–48 hours and MIC (AUC 24-48 /MIC ratio) exceeded 22.7 or 83.3, respectively, and if the percentage of time above MIC between 24 and 48 hours (%T 24-48 >MIC) was greater than 69.0. The probability of target attainment (PTA) was assessed using Monte Carlo simulations ( n = 2,000) for each scenario. A two-compartment model incorporating body (1.6 L/h) and dialysis (2.0 L/h) clearance identified eGFR, dialyzate flow rate (Q D ), and time after first dose as significant covariates. Considering the AUC 24-48 /MIC ratio, 8 g three times daily (TID) was bactericidal (PTA≥90%) in all scenarios at MIC 32 , 5 g TID was bacteriostatic (PTA≥90%) at MIC 64 , and 8 g TID was also effective (PTA≥90%) at MIC 128 . Based on the %T 24-48 >MIC, 4 g TID and 8 g TID were bactericidal (PTA≥90%) at MIC 32 and MIC 64 , respectively. In conclusion, a dosage of 12–24 g/d intravenous fosfomycin is plausible for critically ill patients undergoing CKRT or PIKRT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FosfomycinAnti-Bacterial AgentsRenal Replacement TherapyHumansCritical IllnessMicrobial Sensitivity TestsMiddle AgedAgedMaleFemaleProspective StudiesMonte Carlo MethodGlomerular Filtration RateAdministration, IntravenousAdultArea Under Curve

Stichwörter der Autor:innen

critically illdose optimizationfosfomycinkidney replacement therapypopulation pharmacokinetics

Substanzen

FosfomycinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Saarmetrics GmbH, Saarland University, Saarbrücken, Germany.
  • Department of Clinical Pharmacy, Saarland University, Saarbrücken, Germany.
  • Department of Anaesthesiology, Intensive Care and Pain Therapy, Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg, Germany.
  • University of Queensland Centre for Clinical Research, Faculty of Medicine,The University of Queensland, Brisbane, Queensland, Australia.
  • Herston Infectious Diseases Institute (HeIDI), Metro North Health, Brisbane, Australia.
  • Departments of Pharmacy and Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia.

ORCID-Profile: Katharina M Götz, Thorsten Lehr

Förderung

  • Australian National Health and Medical Research Council

Zitieren

APA

Götz, K. M., Kreuer, S., Volz, A. K., Parker, S. L., Roberts, J. A., Dimopoulos, G., Dimski, T., Kindgen-Milles, D., Beuche, L. K., Kielstein, J. T., & Lehr, T. (2025). Population pharmacokinetics of intravenous fosfomycin: dose optimization for critically ill patients with and without kidney replacement therapy. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01779-24

Vancouver

Götz KM, Kreuer S, Volz AK, Parker SL, Roberts JA, Dimopoulos G, et al. Population pharmacokinetics of intravenous fosfomycin: dose optimization for critically ill patients with and without kidney replacement therapy. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01779-24

BibTeX
@article{Gtz2025,
  author = {Götz, Katharina M and Kreuer, Sascha and Volz, Anke-Katrin and Parker, Suzanne L and Roberts, Jason A and Dimopoulos, George and Dimski, Thomas and Kindgen-Milles, Detlef and Beuche, Lisa K V and Kielstein, Jan T and Lehr, Thorsten},
  title = {Population pharmacokinetics of intravenous fosfomycin: dose optimization for critically ill patients with and without kidney replacement therapy},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.01779-24}
}
Kostenlos starten →